Gene therapy for hemophilia b shows promise in Long-Term study
NCT ID NCT05360706
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 2 times
Summary
This study follows 9 adults with severe or moderately severe hemophilia B who received a one-time gene therapy (AAV5-hFIX) to help their bodies produce clotting factor IX. Researchers are checking if the treatment remains safe and effective for up to 10 years after the initial dose. The goal is to see if this gene therapy can reduce or prevent bleeding episodes over the long term.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
gene therapy (AAV5-hFIX) to produce clotting factor IX
What this could lead to
If successful, this could show that a single gene therapy treatment provides long-lasting control of bleeding episodes, reducing or eliminating the need for regular factor IX infusions.
What could go wrong
This is a small extension study with only 9 participants, so results may not apply to everyone. Long-term safety concerns, such as liver effects or loss of effectiveness over time, are still being monitored.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEMOPHILIA B are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Amsterdam UMC - Locatie AMC
Amsterdam, Netherlands
-
Erasmus MC
Rotterdam, Netherlands
-
Groningen UMC
Groningen, Netherlands
-
Universitaetsklinikum Frankfurt - Klinikum der Johann Wolfgang Goethe Universitae
Frankfurt, Germany
-
Universitair Medisch Centrum Utrecht
Utrecht, Netherlands
-
Vivantes Klinikum im Friedrichshain
Berlin, Germany